Media Center


FDA Warns IBS Drug Viberzi is Associated with an Increased Risk of Pancreatitis For Patients Without a Gallbladder

By Burg Simpson

On March 15, 2017, FDA issued a Drug Safety Communication, warning that patients without a gallbladder who are prescribed the drug Viberzi (eluxadoline) face an increased risk of serious pancreatitis that could result in hospitalization or death. Viberzi is a medicine that is used to treat irritable bowel syndrome with diarrhea (IBS-D).  A recent FDA… Read more »

Top 100 National Trial Lawyers Legal 500 Best Lawyers in America Super Lawyers US News 2014 Top 25 Most Influential Lawyers